| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Robert Ho last filed a Form 4 in February 2022, as Chief Financial Officer at NGNE. Robert Ho's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 21,503 shares of NGNE. The NGNE filings lean toward selling, a net 6,497 shares.
Robert Ho has 5 Form 4 filings on record from March 2020 to February 2022, all as Chief Financial Officer at Neurogene (NGNE), 2020–2022.
The 7 reported transactions were 5 option or other derivative awards, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $72K.
The only open-market sale was 6,497 shares of NGNE at an average $11.01 on March 17, 2021, about $72K. Twelve months later NGNE was down 81%.
Shares as reported in the last Form 4 for each company; the most recent is from February 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2021 | NGNE Neurogene Inc. | Chief Financial Officer | Sale+OE | 6,497 | $11.01 | $71,556.01 | -23.2% | -9.1% | -81.3% |